Embecta Corp. Common Stock (NASDAQ: EMBC)
21 Days left to seek lead plaintiff status.
The Complaint alleges that throughout the Class Period, defendants provided investors with materially false and misleading statements regarding Embecta’s fiscal year 2026 guidance while concealing that the company’s U.S. pen needle segment was experiencing significant competitive and market headwinds that made the guidance unattainable. When Embecta reported its fourth quarter and full year 2025 results on November 25, 2025, the company issued fiscal 2026 guidance calling for adjusted constant currency revenue to be flat to down 2% compared to 2025 levels, translating to an as-reported revenue range of $1.071 billion to $1.093 billion. CEO Devdatt Kurdikar stated that, in fiscal year 2026, the company intended to “maintain our global leadership position in our core product categories,” while CFO Jacob Elguicze affirmed the guidance was “well aligned with the expectations established in our long-range plan.”